London, UK – 23 June 2022. Actimed Therapeutics Ltd, the clinical stage company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders announces that its Chief Medical Officer, Frank Misselwitz MD PhD, will present on the clinical development of its lead candidate S-pindolol benzoate at the 15th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) in Lisbon, Portugal. In addition, he will present conference highlights on the treatment of cancer cachexia and co-chair a session on inter-organ cross-talks in cancer cachexia.

The Company’s co-founder Stefan Anker will also co-chair the conference’s opening session. The presentations will take place both virtually and in Lisbon across 25 - 26 June 2022 and can be viewed live via this link: https://bit.ly/3y9kBcn 

Details for each session are as follows:

Saturday 25 June

Session:                       Opening Session

Time:                           10:00 - 11:00 WEST

Clinical Session:           Inter-organ cross talks in cancer cachexia 

Time:                           10:00 - 10:45 WEST                

Sunday 26 June

Session:                       Late Breaking Trials

Title:                            Use of chirally pure S-enantiomers in the treatment of cancer cachexia: Clinical Development of S-pindolol benzoate in cancer cachexia in patients with advanced Non-Small Cell Lung and Colo-Rectal Cancer

Time:                           13:00 - 13:50 WEST

Session:                       Conference Highlights

Title:                            Treatment of Cancer Cachexia 

Time:                           15:00 - 15.50 WEST

About Actimed Therapeutics  

Actimed Therapeutics is a clinical stage biopharmaceutical company focused on bringing innovation to the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. Actimed was founded in 2017 by Stefan Anker and Andrew Coats, two world leading physicians in muscle wasting research.  

The lead area of focus for Actimed is specifically in cachexia. Cachexia is a wasting disease that accompanies cancer and other serious chronic illnesses and is associated with significant morbidity and mortality. Despite its prevalence and devastating clinical effects, there is no globally approved drug for the treatment or prevention of cancer-related cachexia.  

It has been estimated that cachexia affects 50–80% of cancer patients and accounts for up to 20% of cancer deaths. Treating cancer cachexia successfully may increase both the length and quality of life for cancer patients.  

The lead product of Actimed, S-pindolol benzoate (ACM-001.1) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase II clinical data in cachexia patients. Actimed is currently preparing for further clinical studies in cachexia in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC).  

Actimed has also licensed the global rights to develop and commercialise S-oxprenolol, for cancer cachexia and any other indications outside of amyotrophic lateral sclerosis (ALS) to Faraday Pharmaceuticals. Actimed retains global rights to S-oxprenolol in ALS, where loss of body mass and muscle wasting may impact survival.

About SCWD

SCWD is a non-profit scientific organization comprised of an international and multidisciplinary group of health-care professionals primarily active in these fields that seeks to further research on cachexia and sarcopenia and wasting disorders and bring practical solutions to health-care teams worldwide grappling with treatment.

SCWD was founded to improve patient health worldwide and to encourage prevention and treatment of these conditions. The spectrum of clinical disorders represented by the SCWD Society includes, but is not limited to cachexia, sarcopenia, the syndrome of muscle wasting associated to cancer, COPD, diabetes, heart failure, HIV/ Aids, malnutrition, aging and other chronic conditions.